MedPacto Past Earnings Performance
Past criteria checks 0/6
MedPacto's earnings have been declining at an average annual rate of -29.3%, while the Biotechs industry saw earnings growing at 9.2% annually.
Key information
-29.3%
Earnings growth rate
-27.3%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | n/a |
| Return on equity | -45.8% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Revenue & Expenses BreakdownBeta
How MedPacto makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -35,325 | 4,421 | 24,164 |
| 30 Sep 23 | 0 | -42,452 | 4,225 | 30,651 |
| 30 Jun 23 | 0 | -44,620 | 4,184 | 30,472 |
| 31 Mar 23 | 0 | -45,069 | 4,341 | 29,748 |
| 31 Dec 22 | 0 | -35,753 | 5,074 | 31,919 |
| 30 Sep 22 | 0 | -28,514 | 5,391 | 24,230 |
| 30 Jun 22 | 0 | -26,742 | 5,407 | 27,227 |
| 31 Mar 22 | 0 | -20,476 | 5,116 | 28,490 |
| 31 Dec 21 | 0 | -17,040 | 4,607 | 24,551 |
| 30 Sep 21 | 0 | -17,558 | 4,412 | 26,113 |
Quality Earnings: A235980 is currently unprofitable.
Growing Profit Margin: A235980 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if A235980's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare A235980's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A235980 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (28.8%).
Return on Equity
High ROE: A235980 has a negative Return on Equity (-45.83%), as it is currently unprofitable.